Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Overview of Important Developments on August 20th at Noon

Overview of Important Developments on August 20th at Noon

金色财经金色财经2024/08/20 04:51
Show original

7:00-12:00 Keywords: Parcl, ENS Labs, Curve, Musk

1. Parcl's official website frontend suspected of being attacked;

2. ENS Labs announces personnel changes, Katherine Wu to become the new Chief Operating Officer;

3. Democratic donor Ron Conway leaves the cryptocurrency super PAC;

4. Japanese listed company Metaplanet spends another 500 million yen to increase its holdings by approximately 57.273 BTC;

5. Bitcoin mining company Marathon executives met with the chairman of the Democratic National Committee earlier this month;

6. Curve founder proposes funding support of $6.37 million in CRV for Curve development company;

7. Musk posts an image containing "D.O.G.E." on the X platform, jokingly calling it an abbreviation for "Department of Government Efficiency";

8. Jupiter: Discovered a malicious Chrome extension named "BullChecker," advises users to delete it immediately.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds